menu
    • menu
    [{"orgOrder":0,"company":"Highmark","sponsor":"UCB Pharma S.A","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Antibody-drug Conjugate","year":"2020","type":"Agreement","leadProduct":"Certolizumab Pegol","moa":"TNF-alpha","graph1":"Immunology","graph2":"Approved FDF","graph3":"Highmark","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Highmark \/ UCB Pharma S.A","highestDevelopmentStatusID":"15","companyTruncated":"Highmark \/ UCB Pharma S.A"}]

    Find Clinical Drug Pipeline Developments & Deals by Highmark

    Menu

    Highmark

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Highmark

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed

                            Highmark

                            U.S.A arrow
                            AIChE Annual Meeting
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Study Phase : Approved FDF

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Highmark Forges Outcomes-Based Contract with UCB for Anti-Inflammatory Drug CIMZIA® (certolizumab pegol)

                            Details : The outcomes-based agreement for the CIMZIA lyophilized powder healthcare professional administered formulation applies to all commercial members in Highmark's national and core health insurance markets in Pennsylvania, West Virginia, and Delaware.

                            Product Name : Cimzia

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Undisclosed

                            August 18, 2020

                            Lead Product(s) : Certolizumab Pegol

                            Therapeutic Area : Immunology

                            Highest Development Status : Approved FDF

                            Sponsor : UCB Pharma S.A

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth